Gilead Commits $7.8B to Arcellx CAR-T and $2.2B for Autoimmune Therapy
Gilead Sciences agreed to buy Arcellx for $7.8bn to acquire anito-cel, an anti-BCMA CAR-T therapy with fast-track designation and Phase III launches projecting $658m sales by 2032. It also will pay up to $2.2bn for Ouro Medicines’ T-cell engager platform targeting four autoimmune indications, broadening its pipeline beyond HIV treatments.
1. Arcellx Acquisition Details
Gilead agreed to acquire Arcellx for $7.8 billion to secure global rights to anito-cel, an autologous anti-BCMA CAR-T therapy for patients with relapsed or refractory multiple myeloma. The therapy received FDA fast-track designation and has launched Phase III trials iMMagine-2 and iMMagine-3 targeting earlier treatment lines.
2. Anito-cel Market Potential and Competitive Position
Data from the iMMagine-1 trial showed strong progression-free survival results, projecting anito-cel sales of $658 million by 2032 across eight major markets. Anito-cel’s 17-day manufacturing turnaround and lower severe CRS and neurotoxicity rates versus competitors Carvykti and Abecma position it for cost advantages and broader patient access.
3. Ouro Medicines Acquisition
Gilead will pay up to $2.2 billion for Ouro Medicines, including $1.7 billion upfront and $500 million in milestones, to gain its early-stage T-cell engager platform targeting four autoimmune disease indications. This deal extends Gilead’s pipeline beyond its HIV core, potentially leveraging the therapy for oncology applications.